New advances in the antiretroviral therapy
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.author | Siddiqui, Zain ul Abdin | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Megyeri, Attila | |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.opponentdept | Kenézy Kórház Aneszteziológiai és Intenziv Therápiás Osztály | hu_HU |
| dc.date.accessioned | 2022-08-17T08:32:45Z | |
| dc.date.available | 2022-08-17T08:32:45Z | |
| dc.date.created | 2022 | |
| dc.description.abstract | Today, the standard of care for HIV management is the combination antiretroviral therapy, which utilizes multiple antiretrovirals from various classes to achieve long-term viral suppression. This is a highly effective technique for treating infection and preventing virus transmission. The range of antiretroviral therapy has expanded as a consequence of extensive research into viral pathogenesis. The inclusion of novel antiretroviral agents, particularly first-in-class inhibitors, reflects a paradigm shift towards the identification of compounds that act on new viral targets during the replication cycle. Despite such advanced treatment choices, some obstacles remain in terms of safety profiles, drug adherence, and affordability. For these very reasons, research is still ongoing to discover drugs that can be delivered alternatively to per os, to formulate simplified drug regimens such as 2-drug combinations, to identify long-acting drugs with improved pharmacokinetic properties, and to develop investigational drugs, all of which will help improve adherence and increase the overall efficacy of antiretroviral therapy. Future options might include latency-reversing drugs, broadly neutralizing antibodies, and therapeutic vaccines, which would help further optimize antiretroviral therapy by assisting in achieving a functional cure. | hu_HU |
| dc.description.corrector | hbk | |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 45 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/336530 | |
| dc.language.iso | en | hu_HU |
| dc.subject | Antiretrovirals | hu_HU |
| dc.subject | HIV | hu_HU |
| dc.subject | Novel therapies | hu_HU |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
| dc.title | New advances in the antiretroviral therapy | hu_HU |